Boris Tchernychev Email & Phone Number

451 D Street Suite 911, Boston, Ma 02210

301 Binney St., Cambridge Ma 02142

Olinciguat/Sickle Cell Disease program:• Preclinical pharmacology LEAD for Olinciguat/Sickle Cell Disease (SCD) program.• Generated preclinical data resulting in approval of application for Orphan Drug Designation (ODD).• Ensured evaluation of sGC stimulator olinciguat in animal models of sickle cell crisis and nephropathy.• Led evaluation of olinciguat in in vitro and ex vivo assays.• Conducted preclinical validation of biomarkers for STRONG SCD Phase II study.• Established and oversaw collaborations with key leaders in SCD research.• Presented data to KOLs and at professional meetings and conferences.• Wrote non-clinical pharmacology sections for IND and ODD application, IB, and patent application.• Evaluated and identified potential hematological and vascular rare disease indications for sGC stimulators.Linaclotide (LINZESS)/IBS-C & CIC program:• Contributed to design and completion of FDA approved post-marketing requirement study.• Performed preclinical studies to understand MOA of linaclotide on secretion and visceral pain.• Set up in vitro and ex vivo assays to study linaclotide pharmacology in intestinal mucosa.• Demonstrated the role of MRP4 in regulation of linaclotide-induced electrolyte secretion.• Established and managed collaborations with CROs and academia.• Authored study reports and scientific manuscripts.• Presented at professional conferences and Scientific Advisor Board meetings.

Cambridge, Us

• Member of Anchor Scientific Leadership Team (SLT).• Head of in vivo pharmacology.• Planned, initiated, and led evaluation of GPCRs-specific cell-penetrating peptides (pepducins) in animal models.• Designed and conducted PK and internal toxicology studies.• Provided project leadership to CXCR4/HSCs mobilization program to achieve program milestones.• Co-led collaboration with Johnson & Johnson on oncology target.• Established and oversaw collaborations with CROs and academia.• Authored study reports, new invention disclosures, manuscript, and patent applications.• Presented at conferences and at internal project and Scientific Advisory Board meetings.• Evaluated and identified potential therapeutic targets (GPCRs) and indications.

200 Cambridge Park Drive, Cambridge Ma 02140

• Head of intravital microscopy (IVM) facility.• Implemented IVM to evaluate lead candidates in animal models of athero-inflammation and thrombosis.• Developed critical ex vivo assays.• Led in vivo pharmacology studies resulting in out-licensing of PI3-kinase beta inhibitor program to GVK Biosciences LTD.• Supported in vivo evaluation of lead candidate for P-selectin program to advance program to Phase I.• Generated preclinical data to advance cPLA2 program to Development.• Completed validation of valine substituted analog of GPIb/IgG fusion protein in murine models of thrombosis.• Contributed to evaluation of FXR and RAGE antagonists in a mouse model of diabetic nephropathy.

Boston, Massachusetts, United States

• Characterized PK/PD and Bio-Distribution of GPCRs-specific cell penetrating peptides (pepducins) to secure series A funding for Anchor Therapeutics.• Demonstrated the role of platelet-derived MMP-1 in propagation of arterial thrombi.

Boston, Massachusetts, United States

• Discovered and characterized P-selectin in mouse peritoneal macrophages.• Studied the role of P-, E-, L- selectin and PSGL-1 in monocyte trafficking.• Studied phenotype of PSGL-1 knockout mice.

Ph.D., Biology

M.S., Biology